ObjectivesThe objective of this Core A is to provide additional pharmacy facilities to enable the smooth supply and distribution ofdrugs for all projects in this CIPRA program in accordance with the requirements of Good Clinical Practice (GCP).
Specific aims1, to employ a full-time, qualified pharmacist and a pharmacy assistant to be located at HIV-NAT and to supervisepharmacy activity at all project sites2. to employ an existing NIH approved drug management plan3. to expand pharmacy capacity and storage facilities, including an appropriate area for drug labelling4. to provide climate control for drug storage5. to use antiretroviral drugs which require storage at controlled room temperature (< 30 deg C)6. to provide a back-up power generator for the pharmacy at HIV-NAT7. to provide a computer and 'Office' software for accounting of pharmaceutical supplies8. to manage the distribution of drug to project sitesMethodsThis will be achieved by employing a full-time, qualified pharmacist and by expanding pharmacy storage and workingareas into a newly refurbished room of approximately 70 m 2, including an appropriate area for drug labelling inaccordance with GCP. The new pharmacy will be supplied with temperature-controlled air-conditioning (24-hours) and aback-up power generator. A dedicated computer with database software will facilitate proper stock control andaccountability of drugs and a facsimile will enable efficient communication with suppliers and remote project sites. Newdocument and drug storage will be provided at all sites.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI053741-05
Application #
7668252
Study Section
Special Emphasis Panel (ZAI1-EC-A (S4))
Project Start
2008-06-01
Project End
2009-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
5
Fiscal Year
2008
Total Cost
$39,252
Indirect Cost
Name
HIV-Nat, the Thai Red Cross AIDS Rch Center
Department
Type
DUNS #
671556129
City
Bangkok
State
Country
Thailand
Zip Code
10330
Paul, Robert; Apornpong, Tanakorn; Prasitsuebsai, Wasana et al. (2018) Cognition, Emotional Health, and Immunological Markers in Children With Long-Term Nonprogressive HIV. J Acquir Immune Defic Syndr 77:417-426
Paul, Robert; Prasitsuebsai, Wasana; Jahanshad, Neda et al. (2018) Structural Neuroimaging and Neuropsychologic Signatures in Children With Vertically Acquired HIV. Pediatr Infect Dis J 37:662-668
Bunupuradah, Torsak; Hansudewechakul, Rawiwan; Kosalaraksa, Pope et al. (2015) HLA-DRB1454 and predictors of new-onset asthma in HIV-infected Thai children. Clin Immunol 157:26-9
Ananworanich, Jintanat; Kerr, Stephen J; Jaimulwong, Tanyathip et al. (2015) Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children. J Virus Erad 1:196-202
Kerr, Stephen J; Puthanakit, Thanyawee; Vibol, Ung et al. (2014) Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV. AIDS Care 26:1327-35
Intasan, Jintana; Bunupuradah, Torsak; Vonthanak, Saphonn et al. (2014) Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial. AIDS Patient Care STDS 28:296-302
Puthanakit, Thanyawee; Ananworanich, Jintanat; Vonthanak, Saphonn et al. (2013) Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J 32:501-8
Bunupuradah, Torsak; Kosalaraksa, Pope; Vibol, Ung et al. (2013) Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study. AIDS Patient Care STDS 27:596-603
Puthanakit, Thanyawee; Saphonn, Vonthanak; Ananworanich, Jintanat et al. (2012) Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis 12:933-41
Haas, David W; Mootsikapun, Piroon; Ruxrungtham, Kiat et al. (2012) Clinical perspectives on human genetic screening to prevent nevirapine toxicity. Per Med 9:773-782

Showing the most recent 10 out of 16 publications